Your browser is no longer supported. Please, upgrade your browser.
TBIO [NASD]
Translate Bio, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own1.00% Shs Outstand74.52M Perf Week9.97%
Market Cap1.61B Forward P/E- EPS next Y-0.33 Insider Trans-15.04% Shs Float67.18M Perf Month25.35%
Income-53.80M PEG- EPS next Q-0.07 Inst Own86.80% Short Float10.41% Perf Quarter-7.82%
Sales138.80M P/S11.62 EPS this Y63.80% Inst Trans-6.04% Short Ratio5.45 Perf Half Y35.36%
Book/sh4.79 P/B4.28 EPS next Y-43.50% ROA-8.40% Target Price24.25 Perf Year110.46%
Cash/sh8.32 P/C2.47 EPS next 5Y- ROE-18.90% 52W Range9.64 - 34.64 Perf YTD11.34%
Dividend- P/FCF7.02 EPS past 5Y- ROI-15.50% 52W High-40.76% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low112.86% ATR1.27
Employees122 Current Ratio6.90 Sales Q/Q1221.10% Oper. Margin-39.90% RSI (14)58.64 Volatility5.68% 5.60%
OptionableYes Debt/Eq0.00 EPS Q/Q46.60% Profit Margin-38.70% Rel Volume0.60 Prev Close19.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.28M Price20.52
Recom2.00 SMA2018.37% SMA50-3.92% SMA20010.36% Volume773,019 Change3.74%
Mar-23-21Downgrade SVB Leerink Outperform → Mkt Perform
Mar-18-21Downgrade Truist Buy → Hold $40 → $20
Mar-18-21Downgrade Evercore ISI Outperform → In-line $24 → $21
Oct-05-20Initiated Goldman Buy $19
Jul-07-20Reiterated H.C. Wainwright Buy $18 → $32
Jul-06-20Initiated William Blair Outperform
Jun-26-20Initiated SunTrust Buy $40
Jul-22-19Initiated Jefferies Buy $20
Jun-18-19Initiated ROTH Capital Buy $25
Dec-24-18Initiated H.C. Wainwright Buy $21
Jul-23-18Initiated Leerink Partners Outperform $24
Jul-23-18Initiated Evercore ISI Outperform $25
Jul-23-18Initiated Citigroup Buy $20
Apr-20-21 04:30PM  
Apr-19-21 07:30AM  
07:30AM  
Apr-07-21 04:05PM  
Mar-23-21 04:30PM  
Mar-22-21 07:30AM  
Mar-18-21 04:40PM  
11:36AM  
08:43AM  
08:41AM  
08:24AM  
08:16AM  
07:25AM  
06:53AM  
Mar-17-21 10:44PM  
04:05PM  
11:44AM  
10:30AM  
Mar-15-21 09:29AM  
Mar-12-21 08:12AM  
07:36AM  
05:30AM  
05:29AM  
01:00AM  
01:00AM  
Mar-04-21 01:35PM  
12:30PM  
12:23AM  
Mar-03-21 04:05PM  
Feb-25-21 04:05PM  
Feb-18-21 07:30AM  
Feb-14-21 05:12AM  
Feb-10-21 03:54PM  
Feb-06-21 08:00AM  
Feb-03-21 04:30PM  
Jan-07-21 07:30AM  
Dec-22-20 04:20PM  
Dec-02-20 11:17AM  
Nov-30-20 01:56PM  
Nov-17-20 06:04AM  
Nov-12-20 07:30AM  
Nov-09-20 04:12PM  
Nov-05-20 04:21PM  
Nov-02-20 04:33PM  
Nov-01-20 10:03AM  
Oct-16-20 01:01PM  
Oct-15-20 04:23PM  
01:53PM  
08:00AM  
08:00AM  
Oct-11-20 11:01AM  
Oct-07-20 04:05PM  
12:07PM  
Sep-29-20 04:05PM  
Sep-28-20 06:42PM  
Sep-17-20 01:12PM  
Sep-08-20 07:30AM  
Sep-03-20 04:12PM  
07:30AM  
Aug-14-20 04:55PM  
Aug-06-20 04:14PM  
Jul-31-20 04:55PM  
Jul-30-20 03:52PM  
11:30AM  
Jul-23-20 12:45PM  
Jul-22-20 12:33PM  
Jul-20-20 04:05PM  
Jul-14-20 11:30AM  
Jul-08-20 09:05AM  
Jul-02-20 10:38PM  
Jul-01-20 06:03PM  
10:35AM  
Jun-29-20 08:49AM  
Jun-25-20 11:15PM  
09:36PM  
03:26PM  
07:02AM  
Jun-24-20 04:18PM  
09:33AM  
09:29AM  
Jun-23-20 02:38PM  
01:42PM  
11:40AM  
10:38AM  
10:28AM  
07:57AM  
06:21AM  
03:57AM  
01:48AM  
01:21AM  
12:59AM  
Jun-14-20 08:24PM  
11:16AM  
Jun-03-20 11:41AM  
May-28-20 07:30AM  
May-14-20 11:51AM  
08:47AM  
May-12-20 04:05PM  
May-08-20 06:16PM  
May-07-20 04:26PM  
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Renaud Ronald C JRChief Executive OfficerApr 07Option Exercise7.399,02666,702503,321Apr 09 04:14 PM
Renaud Ronald C JRChief Executive Officer, Pres.Jan 14Option Exercise7.395,63941,673494,205Jan 14 07:59 PM
FORMELA JEAN FRANCOISDirectorDec 22Sale25.0782,5652,069,87043,940Dec 23 06:07 PM
FORMELA JEAN FRANCOISDirectorDec 21Sale25.5056,5361,441,928126,505Dec 23 06:07 PM
Renaud Ronald C JRChief Executive Officer, Pres.Nov 16Option Exercise7.3953,007391,725488,566Nov 18 07:30 PM
FORMELA JEAN FRANCOISDirectorAug 27Sale14.3810,097145,2173,833,122Aug 27 08:14 PM
FORMELA JEAN FRANCOISDirectorAug 26Sale14.8044,381656,7463,843,219Aug 27 08:14 PM
FORMELA JEAN FRANCOISDirectorAug 25Sale15.0034,410516,1603,887,600Aug 27 08:14 PM
Shire Human Genetic Therapies,10% OwnerJun 30Sale20.686,824,992141,140,8350Jun 30 08:24 PM
BAUPOST GROUP LLC/MA10% OwnerJun 26Buy22.00500,00011,000,00018,044,239Jun 30 05:37 PM
Shire Human Genetic Therapies,10% OwnerJun 03Sale19.7540,086791,6986,824,992Jun 05 09:52 AM
Shire Human Genetic Therapies,10% OwnerJun 02Sale19.76105,3952,082,9036,865,078Jun 03 06:08 AM
Shire Human Genetic Therapies,10% OwnerJun 01Sale19.86108,4722,154,1216,970,473Jun 03 06:08 AM